Brian Hess is a Hematology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics need a complete publication history and a confident author match. We omit them when either check fails. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
Sponsor: Medical University of South Carolina
- Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Sponsor: SWOG Cancer Research Network
- Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma
Sponsor: Medical University of South Carolina
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GenentechProgram year20254 paymentsResearch$56,417openpaymentsdata.cms.gov ↗
- GenmabProgram year20258 paymentsResearch$50,536openpaymentsdata.cms.gov ↗
- PfizerProgram year20254 paymentsResearch$17,602openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
43%Kinase inhibitor32.7%Brukinsa82%Calquence18%Part D<11 patientsLeukocyte Growth Factor5.6%Udenyca100%Part D<11 patients+ 1 more class in this area
Dermatology
31.1%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor31.1%Acyclovir100%Part D≥26 patientsMetabolism & gastrointestinal
14.7%Corticosteroid8.4%Prednisone100%Part D≥12 patientsSerotonin-3 Receptor Antagonist6.4%Ondansetron Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2024–2026 per NIH RePORTER. The latest:
- Assessing Metabolically Reprogrammed and Purified CD19-CAR-T in NHL and CLL
Medical University of South Carolina
FY2026$531,092R01CA282408 - Assessing Metabolically Reprogrammed and Purified CD19-CAR-T in NHL and CLL
Medical University of South Carolina
FY2025$532,785R01CA282408 - Assessing Metabolically Reprogrammed and Purified CD19-CAR-T in NHL and CLL
Medical University of South Carolina
FY2024$533,348R01CA282408
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Joseph Antin, MD
Harvard University
Scott Kaufmann, MD
Mayo Clinic College of Medicine
Ruben Mesa, MD
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Jaroslaw Maciejewski, MD
Cleveland Clinic
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”